Clinical Trials
3 trialsNCT00424983 2020-12-21
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
Novartis
Phase 1 Completed
NCT00741377 2013-02-18
A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients
Novartis
Phase 1 Completed
NCT00258258 2013-02-01
Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders
Roswell Park Cancer Institute
Phase 1 Terminated